The Anti-Obesity Drugs Market is expected to register a CAGR of 26% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Anti-Obesity Drugs Market report covers segmental analysis by Drug Class (Peripherally Acting Anti-obesity Drugs, Centrally Acting Anti-obesity Drugs); Medication (Monotherapies, Polytherapies); Drug Type (Prescription Drugs, OTC Drugs), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken down at the regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Anti-Obesity Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Anti-Obesity Drugs Market Segmentation
Drug Class- Peripherally Acting Anti-obesity Drugs
- Centrally Acting Anti-obesity Drugs
- Monotherapies
- Polytherapies
- Prescription Drugs
- OTC Drugs
Strategic Insights
Anti-Obesity Drugs Market Growth Drivers- Rising Obesity Prevalence: The increasing global prevalence of obesity is one of the foremost drivers of the Anti-Obesity Drugs Market. As more individuals across various age groups and regions struggle with overweight and obesity issues, the demand for effective weight management solutions, such as anti-obesity drugs, has surged. Obesity is linked to a range of chronic conditions like diabetes, cardiovascular diseases, and certain cancers, making the need for targeted pharmacological interventions even more urgent.
- Advancements in Drug Development and Efficacy: Continued innovations in drug development are significantly enhancing the effectiveness of anti-obesity medications. Newer drugs with better safety profiles, fewer side effects, and more targeted actions are entering the market. These advancements not only make anti-obesity drugs more appealing to patients but also expand the scope of their application, driving growth in the market.
- Expanding Use of Anti-Obesity Drugs in Personalized Medicine: The shift toward personalized medicine, which tailors treatment to individual patient needs, is opening up new possibilities for the Anti-Obesity Drugs Market. Customized drug regimens based on genetic makeup, lifestyle, and other personal factors are improving the effectiveness of anti-obesity treatments. This approach enhances patient outcomes, thus fueling the demand for anti-obesity drugs tailored to specific populations.
- Emerging Focus on Gut Health and Microbiome: An emerging trend in the Anti-Obesity Drugs Market is the exploration of gut health and the microbiome’s role in obesity management. Growing research suggests that the gut microbiota significantly influences weight regulation and metabolism. As a result, anti-obesity drugs targeting gut microbiome modulation, such as probiotics or prebiotics, will become more prevalent. These therapies may complement traditional weight-loss drugs by promoting healthier digestion and metabolism, offering a new avenue for anti-obesity drug development in the future market.
- Combination of Weight Loss and Comorbidity Treatment: The future of anti-obesity drugs will see an increased focus on medications that address not only obesity but also related comorbidities such as diabetes, hypertension, and high cholesterol. Drugs that combine anti-obesity effects with treatments for these comorbidities will become more common in the market. This trend reflects the growing recognition that obesity often coexists with other chronic health conditions, and multi-functional treatments can improve overall patient outcomes. The market will increasingly offer "dual-purpose" medications that support both weight loss and the management of obesity-related diseases.
- Greater Focus on Safety and Long-Term Efficacy: With growing concerns about the side effects and long-term safety of some current anti-obesity drugs, future developments in the market will prioritize the creation of medications with enhanced safety profiles. New drugs will undergo more rigorous clinical trials and post-marketing surveillance to ensure that they are safe for long-term use. The demand for safer anti-obesity drugs, with fewer side effects and better tolerability, will influence the market as patients seek weight loss solutions that do not compromise their overall health.
- Over-the-Counter (OTC) Anti-Obesity Medications: There is a growing opportunity for the development and commercialization of over-the-counter (OTC) anti-obesity drugs. As consumer demand for weight-loss products increases, there is a rising trend of individuals seeking non-prescription options for weight management. OTC anti-obesity medications can cater to this market, offering consumers greater access to weight-loss treatments without the need for a prescription. This segment of the Anti-Obesity Drugs Market is expected to grow as more consumers opt for convenient, easily accessible weight-loss solutions.
- Increased Collaboration Between Pharmaceutical Companies and Healthcare Providers: The opportunity to collaborate with healthcare providers, including dieticians, nutritionists, and obesity management clinics, is a key growth driver in the Anti-Obesity Drugs Market. Joint initiatives to educate patients on the benefits of anti-obesity drugs, as well as integrated treatment programs that combine drugs with behavioral modifications, can increase market penetration. Pharmaceutical companies that form strong partnerships with healthcare providers can more effectively promote the adoption of anti-obesity drugs and ensure patient adherence to treatment plans.
- Digital Health Integration with Anti-Obesity Drugs: The integration of digital health technologies, such as mobile apps and wearables, with anti-obesity drugs offers a promising opportunity. Digital tools can track a patient’s progress, offer personalized recommendations, and provide real-time feedback on weight loss efforts. This data-driven approach can complement drug therapies, enhancing overall treatment effectiveness. The combination of anti-obesity drugs with digital health tools can create a holistic approach to weight management, further expanding the reach and appeal of anti-obesity medications in the market.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Anti-Obesity Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Anti-Obesity Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Anti-Obesity Drugs Market is expected to register a CAGR of 26% from 2025-2031.
The major factors impacting the Anti-Obesity Drugs Market are: Rising Obesity Prevalence, Advancements in Drug Development and Efficacy, Expanding Use of Anti-Obesity Drugs in Personalized Medicine
Key future trends in this market are - Emerging Focus on Gut Health and Microbiome, Combination of Weight Loss and Comorbidity Treatment and Greater Focus on Safety and Long-Term Efficacy
Key companies of this market are: Arena Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Alizyme plc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Pfizer Inc, Shionogi Inc., Merck and Co., Inc. and Norgine B.V.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-Obesity Drugs Market - By Drug Class
1.3.2 Anti-Obesity Drugs Market - By Medication
1.3.3 Anti-Obesity Drugs Market - By Drug Type
1.3.4 Anti-Obesity Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ANTI-OBESITY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTI-OBESITY DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI-OBESITY DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTI-OBESITY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. PERIPHERALLY ACTING ANTI-OBESITY DRUGS
7.3.1. Overview
7.3.2. Peripherally Acting Anti-obesity Drugs Market Forecast and Analysis
7.4. CENTRALLY ACTING ANTI-OBESITY DRUGS
7.4.1. Overview
7.4.2. Centrally Acting Anti-obesity Drugs Market Forecast and Analysis
8. ANTI-OBESITY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - MEDICATION
8.1. OVERVIEW
8.2. MEDICATION MARKET FORECASTS AND ANALYSIS
8.3. MONOTHERAPIES
8.3.1. Overview
8.3.2. Monotherapies Market Forecast and Analysis
8.4. POLYTHERAPIES
8.4.1. Overview
8.4.2. Polytherapies Market Forecast and Analysis
9. ANTI-OBESITY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG TYPE
9.1. OVERVIEW
9.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
9.3. PRESCRIPTION DRUGS
9.3.1. Overview
9.3.2. Prescription Drugs Market Forecast and Analysis
9.4. OTC DRUGS
9.4.1. Overview
9.4.2. OTC Drugs Market Forecast and Analysis
10. ANTI-OBESITY DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Anti-Obesity Drugs Market Overview
10.1.2 North America Anti-Obesity Drugs Market Forecasts and Analysis
10.1.3 North America Anti-Obesity Drugs Market Forecasts and Analysis - By Drug Class
10.1.4 North America Anti-Obesity Drugs Market Forecasts and Analysis - By Medication
10.1.5 North America Anti-Obesity Drugs Market Forecasts and Analysis - By Drug Type
10.1.6 North America Anti-Obesity Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Anti-Obesity Drugs Market
10.1.6.1.1 United States Anti-Obesity Drugs Market by Drug Class
10.1.6.1.2 United States Anti-Obesity Drugs Market by Medication
10.1.6.1.3 United States Anti-Obesity Drugs Market by Drug Type
10.1.6.2 Canada Anti-Obesity Drugs Market
10.1.6.2.1 Canada Anti-Obesity Drugs Market by Drug Class
10.1.6.2.2 Canada Anti-Obesity Drugs Market by Medication
10.1.6.2.3 Canada Anti-Obesity Drugs Market by Drug Type
10.1.6.3 Mexico Anti-Obesity Drugs Market
10.1.6.3.1 Mexico Anti-Obesity Drugs Market by Drug Class
10.1.6.3.2 Mexico Anti-Obesity Drugs Market by Medication
10.1.6.3.3 Mexico Anti-Obesity Drugs Market by Drug Type
10.2. EUROPE
10.2.1 Europe Anti-Obesity Drugs Market Overview
10.2.2 Europe Anti-Obesity Drugs Market Forecasts and Analysis
10.2.3 Europe Anti-Obesity Drugs Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Anti-Obesity Drugs Market Forecasts and Analysis - By Medication
10.2.5 Europe Anti-Obesity Drugs Market Forecasts and Analysis - By Drug Type
10.2.6 Europe Anti-Obesity Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Anti-Obesity Drugs Market
10.2.6.1.1 Germany Anti-Obesity Drugs Market by Drug Class
10.2.6.1.2 Germany Anti-Obesity Drugs Market by Medication
10.2.6.1.3 Germany Anti-Obesity Drugs Market by Drug Type
10.2.6.2 France Anti-Obesity Drugs Market
10.2.6.2.1 France Anti-Obesity Drugs Market by Drug Class
10.2.6.2.2 France Anti-Obesity Drugs Market by Medication
10.2.6.2.3 France Anti-Obesity Drugs Market by Drug Type
10.2.6.3 Italy Anti-Obesity Drugs Market
10.2.6.3.1 Italy Anti-Obesity Drugs Market by Drug Class
10.2.6.3.2 Italy Anti-Obesity Drugs Market by Medication
10.2.6.3.3 Italy Anti-Obesity Drugs Market by Drug Type
10.2.6.4 Spain Anti-Obesity Drugs Market
10.2.6.4.1 Spain Anti-Obesity Drugs Market by Drug Class
10.2.6.4.2 Spain Anti-Obesity Drugs Market by Medication
10.2.6.4.3 Spain Anti-Obesity Drugs Market by Drug Type
10.2.6.5 United Kingdom Anti-Obesity Drugs Market
10.2.6.5.1 United Kingdom Anti-Obesity Drugs Market by Drug Class
10.2.6.5.2 United Kingdom Anti-Obesity Drugs Market by Medication
10.2.6.5.3 United Kingdom Anti-Obesity Drugs Market by Drug Type
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Anti-Obesity Drugs Market Overview
10.3.2 Asia-Pacific Anti-Obesity Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Anti-Obesity Drugs Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Anti-Obesity Drugs Market Forecasts and Analysis - By Medication
10.3.5 Asia-Pacific Anti-Obesity Drugs Market Forecasts and Analysis - By Drug Type
10.3.6 Asia-Pacific Anti-Obesity Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Anti-Obesity Drugs Market
10.3.6.1.1 Australia Anti-Obesity Drugs Market by Drug Class
10.3.6.1.2 Australia Anti-Obesity Drugs Market by Medication
10.3.6.1.3 Australia Anti-Obesity Drugs Market by Drug Type
10.3.6.2 China Anti-Obesity Drugs Market
10.3.6.2.1 China Anti-Obesity Drugs Market by Drug Class
10.3.6.2.2 China Anti-Obesity Drugs Market by Medication
10.3.6.2.3 China Anti-Obesity Drugs Market by Drug Type
10.3.6.3 India Anti-Obesity Drugs Market
10.3.6.3.1 India Anti-Obesity Drugs Market by Drug Class
10.3.6.3.2 India Anti-Obesity Drugs Market by Medication
10.3.6.3.3 India Anti-Obesity Drugs Market by Drug Type
10.3.6.4 Japan Anti-Obesity Drugs Market
10.3.6.4.1 Japan Anti-Obesity Drugs Market by Drug Class
10.3.6.4.2 Japan Anti-Obesity Drugs Market by Medication
10.3.6.4.3 Japan Anti-Obesity Drugs Market by Drug Type
10.3.6.5 South Korea Anti-Obesity Drugs Market
10.3.6.5.1 South Korea Anti-Obesity Drugs Market by Drug Class
10.3.6.5.2 South Korea Anti-Obesity Drugs Market by Medication
10.3.6.5.3 South Korea Anti-Obesity Drugs Market by Drug Type
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Anti-Obesity Drugs Market Overview
10.4.2 Middle East and Africa Anti-Obesity Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Anti-Obesity Drugs Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Anti-Obesity Drugs Market Forecasts and Analysis - By Medication
10.4.5 Middle East and Africa Anti-Obesity Drugs Market Forecasts and Analysis - By Drug Type
10.4.6 Middle East and Africa Anti-Obesity Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Anti-Obesity Drugs Market
10.4.6.1.1 South Africa Anti-Obesity Drugs Market by Drug Class
10.4.6.1.2 South Africa Anti-Obesity Drugs Market by Medication
10.4.6.1.3 South Africa Anti-Obesity Drugs Market by Drug Type
10.4.6.2 Saudi Arabia Anti-Obesity Drugs Market
10.4.6.2.1 Saudi Arabia Anti-Obesity Drugs Market by Drug Class
10.4.6.2.2 Saudi Arabia Anti-Obesity Drugs Market by Medication
10.4.6.2.3 Saudi Arabia Anti-Obesity Drugs Market by Drug Type
10.4.6.3 U.A.E Anti-Obesity Drugs Market
10.4.6.3.1 U.A.E Anti-Obesity Drugs Market by Drug Class
10.4.6.3.2 U.A.E Anti-Obesity Drugs Market by Medication
10.4.6.3.3 U.A.E Anti-Obesity Drugs Market by Drug Type
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Anti-Obesity Drugs Market Overview
10.5.2 South and Central America Anti-Obesity Drugs Market Forecasts and Analysis
10.5.3 South and Central America Anti-Obesity Drugs Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Anti-Obesity Drugs Market Forecasts and Analysis - By Medication
10.5.5 South and Central America Anti-Obesity Drugs Market Forecasts and Analysis - By Drug Type
10.5.6 South and Central America Anti-Obesity Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Anti-Obesity Drugs Market
10.5.6.1.1 Brazil Anti-Obesity Drugs Market by Drug Class
10.5.6.1.2 Brazil Anti-Obesity Drugs Market by Medication
10.5.6.1.3 Brazil Anti-Obesity Drugs Market by Drug Type
10.5.6.2 Argentina Anti-Obesity Drugs Market
10.5.6.2.1 Argentina Anti-Obesity Drugs Market by Drug Class
10.5.6.2.2 Argentina Anti-Obesity Drugs Market by Medication
10.5.6.2.3 Argentina Anti-Obesity Drugs Market by Drug Type
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ANTI-OBESITY DRUGS MARKET, KEY COMPANY PROFILES
12.1. ARENA PHARMACEUTICALS, INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. F. HOFFMANN-LA ROCHE LTD
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. GLAXOSMITHKLINE PLC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ALIZYME PLC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BOEHRINGER INGELHEIM GMBH
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. NOVO NORDISK A/S
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. PFIZER INC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SHIONOGI INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MERCK AND CO., INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. NORGINE B.V.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Arena Pharmaceuticals, Inc.2. F. Hoffmann-La Roche Ltd3. GlaxoSmithKline plc4. Alizyme plc5. Boehringer Ingelheim GmbH6. Novo Nordisk A/S7. Pfizer Inc8. Shionogi Inc.9. Merck and Co., Inc.10. Norgine B.V.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For